Passage Bio, Inc. announced its fourth‑quarter and full‑year 2025 financial results on March 3, 2026, reporting a net loss of $4.09 per share for the quarter and a net loss of $4.00 per share for the year. The company highlighted progress in its PBFT02 frontotemporal dementia program, noting enrollment of three patients in Cohort 3 of the upliFT‑D study and treatment of a first FTD‑C9orf72 patient with Dose 2. It also outlined plans to report updated interim safety and biomarker data in the first half of 2026 and to seek regulatory feedback on the registrational trial design. The company’s cash runway is projected to extend through the first quarter of 2027, supporting continued clinical development and potential future financing.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.